REG - Oxford Biomedica PLC - Director/PDMR Shareholding

Oxford BioMedicaAnnouncement

17/06/2025 18:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250617:nRSQ2641Na&default-theme=true

RNS Number : 2641N  Oxford Biomedica PLC  17 June 2025

 

PDMR Dealings

 

Oxford, UK - 17 June 2025: OXB (LSE: OXB) (the "Company"), a global quality
and innovation-led cell and gene therapy CDMO, announces that Dr. Heather
Preston, a Non-Executive Director of the Company, has purchased 11,389
ordinary shares of 50p each ("Ordinary Shares") in the Company on 17 June 2025
on the London Stock Exchange at a price of £3.24. Following this purchase,
Dr. Heather Preston holds 29,687 shares representing 0.028% of the Company.

 

The below notifications, made in accordance with the requirements of the EU
Market Abuse Regulation, give further details of the number of ordinary shares
purchased.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Dr. Heather Preston
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £3.24     11,389

 e)  Aggregated information

     -    Aggregate volume                    11,389

     -    Aggregated total

                                              £36,900.36
 f)  Date of the transaction                  2025-06-17
 g)  Place of the transaction                 London Stock Exchange (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

11,389

 

£36,900.36

f)

Date of the transaction

2025-06-17

g)

Place of the transaction

London Stock Exchange (XLON)

 

-Ends-

 

Enquiries:

OXB:

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
(mailto:cosec@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
(mailto:oxb@icrhealthcare.com)

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), a dual-plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer and
packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBLGDLCUBDGUR